Targeting epigenetics and ferroptosis in DLBCL

Abstract excerpt

should encourage us to better address 2 needs in CLL trials enrolling older patients: First, geriatric burden and frailty of trial participants at baseline should be captured and described not only by age, ECOG PS, and the Cumulative Illness Rating Scale, but also by GA. Second, in addition to common hematological end points, such as response, adverse events, and survival, the geriatric burden and frailty should...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer-related gene regulation
• Share to Ferroptosis and cancer prognosis
• Share to RNA modifications and cancer